Aurinia Pharmaceuticals Company Profile (TSE:ISA)

About Aurinia Pharmaceuticals (TSE:ISA)

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:ISA
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%

Frequently Asked Questions for Aurinia Pharmaceuticals (TSE:ISA)

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Tornton Stock Exchange (TSX) under the ticker symbol "ISA."

Who are some of Aurinia Pharmaceuticals' key competitors?

How do I buy Aurinia Pharmaceuticals stock?

Shares of Aurinia Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

Analyst Ratings

Consensus Ratings for Aurinia Pharmaceuticals (TSE:ISA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Aurinia Pharmaceuticals (TSE:ISA)
No equities research coverage for this company has been tracked by


Earnings History for Aurinia Pharmaceuticals (TSE:ISA)
No earnings announcements for this company have been tracked by


Earnings Estimates for Aurinia Pharmaceuticals (TSE:ISA)

No earnings estimates for this company have been tracked by


Dividend History for Aurinia Pharmaceuticals (TSE:ISA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (TSE:ISA)
No insider trades for this company have been tracked by


Headline Trends for Aurinia Pharmaceuticals (TSE:ISA)
Latest Headlines for Aurinia Pharmaceuticals (TSE:ISA)
DateHeadline logoAurinia's Path Forward - November 15 at 3:48 PM logoMid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter Shares Slide - October 6 at 1:20 PM logo16 Stocks Moving In Friday's Pre-Market Session - September 30 at 9:22 AM



Aurinia Pharmaceuticals (ISA) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff